You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 16, 2024

CLINICAL TRIALS PROFILE FOR SYLVANT


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for SYLVANT

Trial ID Title Status Sponsor Phase Start Date Summary
NCT02641522 ↗ Modulation of STAT3 Signaling With Siltuximab in Type 1 Diabetes Completed Janssen Research & Development, LLC Early Phase 1 2016-03-08 The purpose of this study is to evaluate the effects of siltuximab on immune cell functions in patients with Type 1 diabetes (T1D).
NCT02641522 ↗ Modulation of STAT3 Signaling With Siltuximab in Type 1 Diabetes Completed Carla Greembaum, MD Early Phase 1 2016-03-08 The purpose of this study is to evaluate the effects of siltuximab on immune cell functions in patients with Type 1 diabetes (T1D).
NCT02641522 ↗ Modulation of STAT3 Signaling With Siltuximab in Type 1 Diabetes Completed Carla Greenbaum, MD Early Phase 1 2016-03-08 The purpose of this study is to evaluate the effects of siltuximab on immune cell functions in patients with Type 1 diabetes (T1D).
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for SYLVANT

Condition Name

Condition Name for SYLVANT
Intervention Trials
Respiratory Tract Disease 1
Respiratory Tract Infections 1
Schizophrenia 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for SYLVANT
Intervention Trials
Castleman Disease 1
Diabetes Mellitus 1
Lung Diseases 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for SYLVANT

Trials by Country

Trials by Country for SYLVANT
Location Trials
United States 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for SYLVANT
Location Trials
Michigan 2
Georgia 1
Washington 1
Massachusetts 1
North Carolina 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for SYLVANT

Clinical Trial Phase

Clinical Trial Phase for SYLVANT
Clinical Trial Phase Trials
Phase 3 1
Phase 2 2
Phase 1/Phase 2 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for SYLVANT
Clinical Trial Phase Trials
Terminated 2
Completed 1
Not yet recruiting 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for SYLVANT

Sponsor Name

Sponsor Name for SYLVANT
Sponsor Trials
EusaPharma (UK) Limited 2
Janssen Research & Development, LLC 1
Carla Greembaum, MD 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for SYLVANT
Sponsor Trials
Other 6
Industry 4
U.S. Fed 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.